新桥生物宣布，其研发的Givastomig已获得美国食品药品监督管理局（FDA）授予的快速通道资格，该资格针对的适应症为一线治疗HER2阴性转移性胃癌。此项认定有望加速该药物的研发与审评进程。
新桥生物宣布，其研发的Givastomig已获得美国食品药品监督管理局（FDA）授予的快速通道资格，该资格针对的适应症为一线治疗HER2阴性转移性胃癌。此项认定有望加速该药物的研发与审评进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.